Benitec Biopharma (BNTC) EBIT Margin (2019 - 2023)

Benitec Biopharma (BNTC) reported EBIT Margin of 65000.0% for Q2 2023, down 708.57% sequentially from 8038.89% in Q1 2023.

Benitec Biopharma (BNTC) EBIT Margin (2019 - 2023) Analysis & Trends

Benitec Biopharma (BNTC) has 5 years of EBIT Margin data on file, last reported at 65000.0% in Q2 2023.

For the quarter ending Q2 2023, EBIT Margin changed N/A year-over-year to 65000.0%; the trailing twelve-month figure through Mar 2024 stood at 307028.57% (down 27869181.0% YoY), and the FY2023 full-year result was 25441.33%, down 98380.0% from the prior year.
EBIT Margin fell to 65000.0% in Q2 2023, from 8038.89% in the prior quarter.
In the past five years, EBIT Margin ranged from a high of 8248.57% in Q2 2020 to a low of 379300.0% in Q1 2021.
A 5-year average of 80620.4% and a median of 8038.89% in 2023 frame the typical range for EBIT Margin.
Across the five-year window, EBIT Margin plunged 37176071 bps in 2021 and jumped 37209167 bps in 2022, its largest moves.
Tracing BNTC's EBIT Margin over 5 years: stood at 2741.56% in 2019, then slumped by 11787 bps to 325900.0% in 2020, then surged by 94 bps to 19340.0% in 2021, then slumped by 107 bps to 40071.43% in 2022, then plunged by 62 bps to 65000.0% in 2023.
Business Quant data shows BNTC's EBIT Margin at 65000.0% in Q2 2023, 8038.89% in Q1 2023, and 40071.43% in Q4 2022.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	EBIT Margin (Qtr)
1	Oculis Holding AG	68,785.72 Bn	68,785.72 Bn	-	-
2	Nanobiotix	1,895.57 Bn	1,895.51 Bn	-	-
3	BeOne Medicines	471.35 Bn	466.56 Bn	1.35 Bn	16.51%
4	NuCana	279.75 Bn	279.75 Bn	-	-
5	Vertex Pharmaceuticals	120.24 Bn	113.00 Bn	2.59 Bn	38.10%
6	Regeneron Pharmaceuticals	67.80 Bn	59.04 Bn	3.31 Bn	17.83%
7	Belite Bio	62.51 Bn	62.51 Bn	-	-
8	Argenx Se	57.38 Bn	57.38 Bn	1.41 Bn	31.68%
9	Revolution Medicines	37.78 Bn	37.78 Bn	-	-
10	Benitec Biopharma	46.45 Mn	46.45 Mn	-	-

Download Data